General Session 2
Zusammenfassungen erscheinen bald
- GS02-01 Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01
- GS02-02 Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
- GS02-04 Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival
- GS02-05 Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long- term outcomes among 20,273 women in 29 randomised trials
- GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial
- GS02-07 Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
- GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast- conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
- GS02-10 Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
- GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
GS02-01 Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01
Zusammenfassung folgt
Giacomo Montagna, Alison Laws, Massimo Ferrucci, et al.
GS02-02 Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study
Zusammenfassung folgt
Kelly Metcalfe, Jan Lubinski, Jana Soukupová, et al.
GS02-04 Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival
Zusammenfassung folgt
Gurdeep Mannu, Graham Beake, Richard Berry, et al.
GS02-05 Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long- term outcomes among 20,273 women in 29 randomised trials
Zusammenfassung folgt
Jana de Boniface, Tove Tvedskov, Bergkvist Leif, et al.
GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial
Zusammenfassung folgt
Eleftherios Mamounas, Hanna Bando, Julia White et al. (Kopie) (Kopie)
GS02-07 Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304
Zusammenfassung folgt
Kent Griffit, Eleanor Harris, Jean Wright, et al.
GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast- conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
Zusammenfassung folgt
Anne May, Anouk Hiensch, Johanna Depenbusch, et al.
GS02-10 Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study
Zusammenfassung folgt
Hatem Azim, Samuel Niman, Ann Partridge, et al.
GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
Zusammenfassung folgt